Advanced Oncotherapy announces that Sanjeev Pandya, Euan Thomson and Prof Chris Nutting have stood down from the Board. Thomson and Prof Nutting will continue to contribute to the Company's development by becoming members of the Medical Advisory Board. In addition, the Company has agreed that, subject to completing the requisite due diligence procedures, it will appoint Peter Sjostrand, Gabriel Urwitz, Zhang RenHua, Mr. Chunlin Han and Yuelong Huang as Non-Executive Directors. Peter Sjostrand proposed Non-Executive Director and Vice-Chairman. Peter has a long career as an independent Non-Executive Director for a number of public and private companies within the Healthcare, Industrial and Financial areas. Peter is a Director of one of the largest publicly listed biotech companies in Sweden, Active Biotech, and was previously Chairman of the medical technology company Gambro, the biotech firm Innate Pharma and Meda a publicly listed large cap speciality pharma business. Peter has been a Director on the Board of a number of other public healthcare companies, including the pharmaceutical company Astra which was at one stage the largest listed company in Sweden by market cap; Karolinska Development, a biotech holding company; Mediject, a US medical technology business; biotech firm Medivir; and also Nasdaq listed Tularik. Gabriel Urwitz, Segulah Advisor AB - proposed Non-Executive Director. Gabriel Urwitz is founding Partner, Managing Partner and Executive Chairman of Segulah Advisor AB. Segulah is a long-term supporter of the Company with a significant shareholding. Gabriel has a broad background in industry and finance and was adjunct Professor of Financial Economics at the Stockholm School of Economics from 1977 to 2002. He is currently President of the Swedish Private Equity & Venture Capital Association. Gabriel was previously CEO of Richard Hägglöf Fondkommission, Proventus AB, AB Segulah, and Gota Bank and is a Director of Mr. Music, Almondy, PMC Group AB, EEN, Previa, Joy Shop AB, NEA, and Isaberg Rapid. Ms Zhang RenHua is the co-Founder, CEO, and Vice Chairman of the board of Realcan Pharmaceutical Co. Ltd. Chunlin Han serves as Head of Investment and Financing for Realcan Pharmaceuticals Co. Ltd. Yuelong Huang serves as General Manager of Medical Technology Department of Realcan Pharmaceuticals Co. Ltd; he is responsible for all M&A activities and medtech R&D/manufacturing. He is a former Senior Scientist of German Julich Research Center and has over 20 years of experience in R&D, manufacturing and operations in semi-conductor and renewable energy industries. Liquid Harmony and the Han family's extensive knowledge and experience of rolling-out high-end medical equipment in China and internationally will be of great benefit to the Company's commercialisation strategy.